Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/00000542-200305000-00036 | DOI Listing |
Menopause
January 2025
Clinique de Recherche en Santé des Femmes, Québec City, Québec, Canada.
Objective: The aim of the study was to assess the prevalence of postmenopausal vasomotor symptoms (VMS) and the impact of VMS and related treatment patterns among perimenopausal and postmenopausal Canadian women.
Methods: A subgroup analysis of data from a cross-sectional online survey of women aged 40-65 years conducted November 4, 2021, through January 17, 2022, evaluated the prevalence of moderate/severe VMS among postmenopausal Canadian women. The analysis also assessed survey responses from perimenopausal and postmenopausal Canadian women with moderate/severe VMS who completed the Menopause-Specific Quality of Life questionnaire, Work Productivity and Activity Impairment questionnaire, and the Patient-Reported Outcomes Measurement Information System Sleep Disturbances-Short Form 8b and answered questions about treatment patterns and attitudes toward treatments.
Cureus
November 2024
Physical Medicine and Rehabilitation, RG Kar Medical College and Hospital, Kolkata, IND.
A 44-year-old male patient experienced persistent radiating pain from the elbow to the hand following herpes zoster vesicular eruptions three months earlier. His examination met the Budapest Clinical Criteria for Complex Regional Pain Syndrome (CRPS), revealing sensory, motor, vasomotor, and sudomotor signs and symptoms. Despite conservative treatments, the pain persisted.
View Article and Find Full Text PDFObjectives: To assess the efficacy and safety of the non-hormonal, neurokinin 3 receptor antagonist, fezolinetant, to treat moderate-severe vasomotor symptoms associated with menopause in individuals unsuitable for hormone therapy.
Design: Phase 3b randomised controlled trial.
Setting: 16 countries.
Sci Rep
October 2024
Department of Automatic Control Engineering, Feng Chia University, Taichung, 407102, Taiwan.
Postural orthostatic tachycardia syndrome (POTS) presents excessive orthostatic tachycardia and orthostatic intolerance. POTS is a common and therapeutically challenging condition affecting numerous people worldwide. As many disease entities can be confused with POTS, it becomes critical to identify this syndrome.
View Article and Find Full Text PDFSci Rep
October 2024
Department of Physiology and Pharmacology, Robarts Research Institute, Schulich School of Medicine and Dentistry, University of Western Ontario, London, ON, Canada.
Constrictor agonists set arterial tone through two coupling processes, one tied to (electromechanical), the other independent (pharmacomechanical) of, membrane potential (V). This dual arrangement raises an intriguing question: is the contribution of each mechanism (1) fixed and proportionate, or (2) variable and functionally biased. Examination began in mouse mesenteric arteries with a vasomotor assessment to a classic G (phenylephrine) or G/G (U46619) agonist, in the absence and presence of nifedipine, to separate among the two coupling mechanisms.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!